Literature DB >> 11152227

Islet allograft rejection can be mediated by CD4+, alloantigen experienced, direct pathway T cells of TH1 and TH2 cytokine phenotype.

J A Barbara1, S E Turvey, C I Kingsley, B M Spriewald, M Hara, O Witzke, P J Morris, K J Wood.   

Abstract

BACKGROUND: It is widely believed that Thl cells that secrete interferon-gamma are primarily involved in the rejection of allografts whereas Th2 cells [interleukin(IL) 4 and IL-10] are thought to be protective of this process. However, the exact role and specificity of these helper T lymphocytes in mediating allograft damage is presently unknown.
METHODS: Th0, Th1, and Th2 cell lines specific for the class II MHC molecule H2IAb were adoptively transferred into T cell deficient, syngeneic, diabetic mice before transplantation of fully allogeneic C57BL/10 (H2b) or (CBKxBALB/c)F1 (H2k/d+Kb) islet grafts. T cells were 5-(and-6-)-carboxyfluorescein diacetate succinimidyl ester- (CFSE) labeled to allow detection, immunohistochemistry was performed, and IL-4 transcripts within the rejected islet grafts were quantified by reverse transcriptase polymerase chain reaction (RT-PCR).
RESULTS: Adoptive transfer (IV) of Th0-, Th1-, and Th2 IAb-specific T cells resulted in rejection of H2b islet allografts. CFSE-labeling demonstrated that these T cells were able to home to the graft site. CD4+ T cells and CD11b+ macrophages were present within the graft after adoptive transfer of both Thl and Th2 cells. Interestingly, CD8+ T cells and B cells were absent from these rejecting grafts. Even when Th2 cells were introduced directly at the graft site, prompt rejection was still observed despite the presence of increased IL-4 mRNA expression within the islet allografts.
CONCLUSIONS: Th2 and Th0 alloreactive CD4+ T helper cells can reject islet grafts with similar efficiency to Th1 cells. These results suggest that deviation of the immune response from a Th1 to Th2 phenotype will not be sufficient to allow successful engraftment of allogeneic organs or tissues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11152227     DOI: 10.1097/00007890-200012150-00017

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  IL-4 expression delays eosinophil-independent vasculopathy and fibrosis during allograft rejection in the mouse.

Authors:  Edda M Roberts; De Shon Hall; Sharon Ferguson; Susan Minson; Joanna D Davies
Journal:  J Clin Immunol       Date:  2003-03       Impact factor: 8.317

Review 2.  Routes to transplant tolerance versus rejection; the role of cytokines.

Authors:  Patrick T Walsh; Terry B Strom; Laurence A Turka
Journal:  Immunity       Date:  2004-02       Impact factor: 31.745

Review 3.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

4.  Effects of streptozotocin on autoimmune diabetes in NOD mice.

Authors:  M Koulmanda; A Qipo; H Auchincloss; R N Smith
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

5.  Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4+CD25+ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor.

Authors:  Bruce M Hall; Rachael M Hall; Giang T Tran; Catherine M Robinson; Paul L Wilcox; Prateek K Rakesh; Chuanmin Wang; Alexandra F Sharland; Nirupama D Verma; Suzanne J Hodgkinson
Journal:  Front Immunol       Date:  2021-11-29       Impact factor: 7.561

Review 6.  Transplant Tolerance, Not Only Clonal Deletion.

Authors:  Bruce M Hall; Nirupama D Verma; Giang T Tran; Suzanne J Hodgkinson
Journal:  Front Immunol       Date:  2022-04-21       Impact factor: 8.786

Review 7.  The Immunological Basis of Liver Allograft Rejection.

Authors:  Vincenzo Ronca; Grace Wootton; Chiara Milani; Owen Cain
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.